#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk)


Authors: Payer Juraj 1;  Tomková Soňa 2;  Killinger Zdenko 1;  Brázdilová Kristina 1;  Jackuliak Peter 1;  Vaňuga Peter 3;  Letkovská Alexandra 4;  Masaryk Pavol 4;  Kmečová Zlata 5;  Kužma Martin 1
Authors‘ workplace: Comenius University Medical Faculty, 5th Department of Internal Medicine, University Hospital Bratislava, Slovakia 1;  Osteocentrum, Hospital Košice-Šaca, Košice, Slovakia 2;  National Institute of Endocrinology and Diabetology, Lubochňa, Slovakia 3;  National Institute of Rheumatic Diseases, Piešťany, Slovakia 4;  Osteocentrum of F. D. Roosevelt Faculty Hospital, Banská Bystrica, Slovakia 5
Published in: Clinical Osteology 2018; 23(4): 138-145
Category:

Overview

Úvod:

Liečba glukokortikoidmi má za následok rýchlu stratu denzity kostného minerálu (BMD) a glukokortikoidmi indukovaná osteoporóza (GIOP) je najčastejšou a závažnou formou sekundárnej osteoporózy. Liečba žien s post­menopauzálnou osteoporózou teriparatidom (TPTD) významne zvyšuje trabekulárny kostný objem a konektivitu, zlepšuje trabekulárnu morfológiu s posunom smerom k viac doštičkovitej štruktúre a zvyšuje hrúbku kortikálnej kosti.

Ciel štúdie:

Posúdení zmeny BMD a trabekulárneho kostného skóre (TBS) po 12- a 18-mesačnej liečbe TPTD u pacientov s GIOP.

Pacienti a metódy:

Prospektívne multicentrické, nekontrolované sledovanie účinnosti a bezpečnosti liečby TPTD u pacientov s GIOP, uskutočňované v 5 špecializovaných centrách ustanovených pre liečbu TPTD. U všetkých pacientov zaradených do registru OSTEO.sk bolo pravidelne uskutočňované meranie BMD v bedrovej chrbtici a proximálnom femoru a sledovanie markerov kostného obratu. V podskupine účastníkov bolo merané TBS.

Výsledky:

Z celkového počtu 263 pacientov zaradených do registra bolo do záverečnej analýzy zahrnutých 129 pacientov (20 mužov vo veku 51,5 let/109 žien vo veku 59,7 let). Po liečbe TPTD bol zistený v porovnaní s východiskovými hodnotami nárast BMD v bedrovej chrbtici v 12. mesiaci (+ 8,3 %, p < 0,001) a v 18. mesiaci nárast BMD hlavica femoru (+ 3,85 %, p < 0,001), krčku femoru (+ 3,26 %, p < 0,001) a bedrovej chrbtice (+ 9,28 %, p < 0,001). V podskupine (n = 12) v priebehu prvých 12 mesiacov narástlo TBS o 2,4 % (p = 0,01). 18-mesačná liečba TPTD viedla k významnému zvýšení markerov kostného obratu.

Záver:

18-mesačná liečba TPTD viedla k významnému zvýšeniu BMD so súčasným zvýšením všetkých hodnotených markerov kostného obratu. Okrem toho bolo v podskupine účastníkov štúdie pozorované zvýšenie TBS po 12 mesiacoch liečby. Podľa týchto výsledkov bolo preukázané, že u pacientov s GIOP je TPTD vysoko účinný osteoanabolický liek.

Klíčová slova:

kostná minerálna denzita (BMD) – osteoporóza indukovaná glukokortikoidmi (GIOP) – trabekulárne kostné skóre (TBS) – teriparatide


Sources
  1. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10): 777–787. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980200108>.
  2. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf 2010; 2: 49–59.
  3. Dale Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16(1): 97–103. Dostupné z DOI:<http://dx.doi.org/10.1359/jbmr.2001.16.1.97>.
  4. Van Staa TP, Leufkens HGM, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000; 39(12): 1383–1389.
  5. Van Staa T, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6): 993–1000. Dostupné z DOI:<http://dx.doi.org/10.1359/jbmr.2000.15.6.993>.
  6. De Gregório LH, Lacativa PG, Melazzi AC et al. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol 2006; 50(4): 793–801.
  7. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79(3): 129–137. Dostupné z DOI:<http://dx.doi.org/10.1007/s00223–006–0019–1>.
  8. Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 2009; 5(2): 305–310.
  9. Lekamwasam S, Adachi JD, Agnusdei D et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23(9): 2257–2276. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–012–1958–1>.
  10. Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18(11): 1932–1941. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.11.1932>.
  11. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>.
  12. Rizzoli R, Adachi JD, Cooper C et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012; 91(4): 225–243. <http://dx.doi.org/10.1007/s00223–012–9630–5>.
  13. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am 2012; 41(3): 507–525. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ecl.2012.05.002>.
  14. Vanuga P, Tomkova S, Masaryk P et al. Slovak register of patient with severe osteoporosis on osteoanabolic treatment. Osteoporos Int 2012; 23(Suppl 2): S239-S240.
  15. Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Open Pharmacother 2013;14(2):185–97. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2013.761975>.
  16. Amiche MA, Albaum JM, Tadrous M et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int 2016; 27(6): 1989–1998. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3476–4>.
  17. Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs 2008; 68(18): 2709–2737. Dostupné z DOI: <http://dx.doi.org/10.2165/0003495–200868180–00012>.
  18. Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 2008; 42(4): 775–787. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2007.11.018>.
  19. Hans D, Goertzen AL, Krieg MA et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011; 26(11): 2762–2769. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.499>.
  20. Briot K, Paternotte S, Kolta S et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone 2013; 57(1): 232–236. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2013.07.040>.
  21. Boutroy S, Hans D, Sornay-Rendu E et al. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int 2013; 24(1): 77–85. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–012–2188–2>.
  22. Iki M, Tamaki J, Kadowaki E et al. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 2014; 29(2): 399–407. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2048>.
  23. Senn C, Gunther B, Popp AW et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 2014; 25(7): 1945–1951. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–014–2703–8>.
  24. Saag KG, Agnusdei D, Hans D et al. Trabecular Bone Score in Patients With. Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis Rheumatol 2016; 68(9): 2122–2128. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39726>.
  25. Miyaoka D, Imanishi Y, Ohara M et al. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine. Bone Mineral Density and Microarchitecture in Osteoporosis. Calcif Tissue Int 2017; 101(4): 396–403. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–017–0295-y>.
  26. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating of glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346–3355. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24879.
  27. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028–2039. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071408>.
  28. McClung MR, San Martin J, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165(15): 1762–1768. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.15.1762>.
  29. Keaveny TM, Donley DW, Hoffmann PF et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007; 22(1): 149–157. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.061011>.
  30. O´Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strenght. Endocrinology 2004; 145(4): 1835–1841. <http://dx.doi.org/10.1210/en.2003–0990>.
  31. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15(6): 1006–1013. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2000.15.6.1006>.
  32. Reid DM, Adami S, Devogelaer JP et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69(4): 242–247.
  33. Neer RM, Claude DA, Jose RZ et al. Effect of Parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>.
  34. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44(1): 202–211. Dostupné z DOI: <http://dx.doi.org/10.1002/1529–0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W>.
  35. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18(5): 919–924. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.5.919>.
  36. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67(4): 277–285.
  37. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(9): 1434–1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>.
  38. Murphy DR, Smolen LJ, Klein TM et al. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord 2012; 13: 213. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2474–13–213>
  39. Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: An update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2013; 14(2): 185–197. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2013.761975>.
  40. Gluer CC, Marin F, Ringe JD et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Rheumatol 2012; 39(3): 600–609.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#